Today's top gainers include SL Science, which was recently listed on the Nasdaq; Chemomab, gearing up for a Phase 3 trial in primary sclerosing cholangitis; Propanc, following the launch of a share repurchase program; and Tectonic, drawing investor attention ahead of key clinical trial catalysts, among others.